Post-earnings recap
Reported
Thu, Jul 26, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bristol Myers Squibb's earnings report shows a solid EPS beat, which indicates strong underlying performance. However, the stock declined by 1.9%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more comprehensive information on the company's future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.01 | N/A | +13.95% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of optimism regarding their drug portfolio. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted the strong performance in their key drug segments.
They expressed confidence in ongoing clinical trials and pipeline developments.